Primary Biliary Cholangitis Clinical Trials

Find Primary Biliary Cholangitis Clinical Trials Near You

Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg/Day in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.

Status: Active_not_recruiting
Location: See all (72) locations...
Study Type: Observational
SUMMARY

This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting. PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms including pruritus (itching) and fatigue. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. In this study the main aim is to observe the effectiveness, safety and tolerability of elafibranor in participants with PBC who are receiving treatment in real world setting. The total study duration for each participants will be 60 months (approximately 5 years).

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Participant has provided written informed consent and agrees to comply with the study protocol.

• Participant with PBC diagnosis.

• Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor.

• If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.

Locations
United States
California
Southern California Research Center
Coronado
Cedars-Sinai Medical Center
Los Angeles
University of California Davis Medical Center
Sacramento
Colorado
South Denver Gastroenterology,P.C.
Englewood
Connecticut
Yale University School of Medicine
New Haven
Florida
Schiff Center for Liver Diseases - University of Miami
Miami
Massachusetts
Beth Israel Deaconess Medical Center, Liver Research Center
Boston
North Carolina
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill
New Jersey
Virtua Center for Liver Disease - Cherry Hill
Cherry Hill
New York
Northwell Health Inc, Center for Liver Disease and Transplantation
Manhasset
Ohio
Cleveland Clinic Foundation
Cleveland
South Carolina
Medical University of South Carolina (MUSC)
Charleston
Texas
Liver Center of Texas
Dallas
Baylor College of Medicine - Advanced Liver Therapies
Houston
Texas Digestive Specialists
Mcallen
Utah
Intermountain Medical Center
Murray
Virginia
Bon Secours Richmond Community Hospital LLC. d/b/a Bon Secours Liver Institute of Richmond
Richmond
Virginia Commonwealth University Medical Center - West Hospital
Richmond
Washington
Velocity Clinical Research
Seattle
Other Locations
Australia
Royal Prince Alfred Hospital
Camperdown
St Vincent's Hospital
Fitzroy
Austria
Medizinische Universitaetsklinik Graz
Graz
Medical University Innsbruck
Innsbruck
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz
Canada
University of Calgary
Calgary
London Health Sciences Centre (LHSC) - University Hospital
London
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
Montreal
The Ottawa Hospital - General Campus
Ottawa
(G.I.R.I) GI Research Institute Foundation
Vancouver
Germany
Charite Universitatsmedizin Berlin
Berlin
DRK Kliniken Berlin Mitte
Berlin
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt
Studiengesellschaft BSF
Halle
Gastroenterologsiche Studiengesellschaft Herne
Herne
Universitaet des Saarlandes
Homburg
Universitaetsklinikum Leipzig
Leipzig
Greece
General Hospital of Athens Laiko
Athens
University Hospital of Heraklion
Heraklion
University General Hospital of Larissa
Larissa
University General Hospital of Patras
Pátrai
Ippokratio General Hospital of Thessaloniki
Thessaloniki
Italy
ASST-Ospedale Papa Giovanni XXIII
Bergamo
Ospedale Garibaldi Nesima
Catania
Universita Degli Studi Di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC)
Florence
ASST Grande Ospedale Metropolitano Niguarda
Milan
Ospedale Maggiore Della Carita
Novara
A. Gemelli University Hospital, Catholic University of the Sacred Heart
Roma
Fondazione Policlinico Universitario Campus Bio-Medico
Roma
Republic of Korea
Pusan National University Hospital (PNUH)
Busan
Seoul National University Bundang Hospital (SNUBH)
Seongnam-si
Samsung Medical Center
Seoul
Seoul National University Hospital
Seoul
Severance Hospital, Yonsei University Health System
Seoul
Spain
Hospital de Torrecardenas
Almería
Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona
Hospital Universitario Vall d'Hebron
Barcelona
Hospital General Universitario Gregorio Maranon (HGUGM)
Madrid
Complexo Hospitalario Universitario de Pontevedra
Pontevedra
Instituto De Investigacion Marques De Valdecilla (IDIVAL)
Santander
United Arab Emirates
Clemenceau Medical Center Hospital
Dubai
Mediclinic Airport Road Hospital
Dubai
Rashid Hospital
Dubai
Sheikh Shakhbout Medical City
Dubai
United Kingdom
Aberdeen Royal Infirmary NHS Grampian Grampian Health Board
Aberdeen
Belfast Health and Social Care Trust - Royal Victoria Hospital
Belfast
Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust
Birmingham
Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation
Bradford
Hull Royal Infirmary - Hull University Teaching Hospitals NHS Trust
Hull
King's College Hospital NHS Foundation Trust
London
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital
Newcastle
Queen's Medical Centre - Nottingham University Hospitals NHS Trust
Nottingham
John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust
Oxford
Time Frame
Start Date: 2024-10-14
Completion Date: 2032-07-15
Participants
Target number of participants: 424
Sponsors
Leads: Ipsen

This content was sourced from clinicaltrials.gov

Similar Clinical Trials